SA Prepares for Snakebite Season: Sufficient Antivenom Stock Confirmed

As South Africa heads into the peak of its snakebite season, concerns regarding the supply of antivenom have been put to rest. In a crucial development, the National Snakebite Advisory Group has reassured the public and health officials that the country is well stocked with antivenom, easing fears of a potential shortage ahead of the summer months when snake encounters increase.

The reassuring news comes after proactive measures were taken by the National Snakebite Advisory Group, which had previously urged Health Minister Dr. Joe Phaahla to secure funding and necessary equipment upgrades to avoid shortages. These measures appear to have borne fruit, as confirmed by Professor Timothy Craig Hardcastle, the spokesperson for the group. Their efforts ensured that the South African Vaccine Producers (SAVP), a division of the National Health Laboratory Service (NHLS), has a healthy supply of this life-saving medication.

Mzimasi Gcukumana, the NHLS's senior communications manager, provided concrete numbers to underscore the sufficiency of the antivenom stockpile. He mentioned that between January 1 and November 16, no fewer than 6,100 vials of antivenom were distributed to 302 medical institutions within South Africa. This distribution included 76 health facilities in the Western Cape province alone. Furthermore, Byron la Hoe, a representative of the Western Cape Department of Health and Wellness, confirmed the regional availability of antivenom, with 242 vials being acquired for the period of October 2022 to September 2023, ensuring readiness to cope with any snakebite incidents.

Although snakebite occurrences vary from year to year, Netcare, a prominent private healthcare provider, has reported 27 snakebites so far. Mande Toubkin, the general manager of emergency, trauma, transplant and corporate social investment at Netcare, underlined that the number could rise, as the majority of snakebites typically happen during the summer months, from December to March.

Proactively, two types of snake antivenom are produced domestically to cover various snake species in the region. Polyvalent antivenom is effective against bites from numerous dangerous snakes such as the mambas, cobras, and adders. The monovalent vaccine is specifically designed to counteract boomslang bites.

The African Snakebite Institute has previously outlined the cost and required dosages of these antivenoms, emphasising the necessity of correct administration depending on the type of bite. Cost considerations are also significant, as vials range from R2,130 for polyvalent to R6,800 for monovalent antivenom.

Awareness and preventive measures are at the forefront of addressing the snakebite issue, as pointed out by Steven Meighan of the Deep South Reptile Rescue and the Herpetological Association of the Western Cape. Meighan's advice revolves around keeping homes and gardens clean to avoid attracting rodents, which in turn attract snakes. This proactive approach mirrors the national efforts to mitigate snakebite risks through education and readiness.

In conclusion, South Africa's preparedness for the snakebite season is now on solid ground, with ample antivenom supply and concerted efforts to promote awareness and prevention among the public. As the country navigates through these risky months, the collaborative actions of health experts, healthcare providers, and the government offer reassurance and a blueprint for effectively managing potential snakebite crises.